GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sonoma Pharmaceuticals Inc (STU:O8Z) » Definitions » Earnings per Share (Diluted)

Sonoma Pharmaceuticals (STU:O8Z) Earnings per Share (Diluted) : €-9.46 (TTM As of Jun. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Sonoma Pharmaceuticals Earnings per Share (Diluted)?

Sonoma Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Jun. 2024 was €-1.30. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was €-9.46.

Sonoma Pharmaceuticals's EPS (Basic) for the three months ended in Jun. 2024 was €-1.30. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 was €-9.46.

Sonoma Pharmaceuticals's EPS without NRI for the three months ended in Jun. 2024 was €-1.30. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 was €-9.46.

During the past 3 years, the average EPS without NRIGrowth Rate was 39.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was 41.90% per year. During the past 10 years, the average EPS without NRI Growth Rate was 33.80% per year.

During the past 13 years, Sonoma Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 56.40% per year. The lowest was -361.20% per year. And the median was 28.70% per year.


Sonoma Pharmaceuticals Earnings per Share (Diluted) Historical Data

The historical data trend for Sonoma Pharmaceuticals's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sonoma Pharmaceuticals Earnings per Share (Diluted) Chart

Sonoma Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -40.54 -33.10 -34.87 -28.39 -9.75

Sonoma Pharmaceuticals Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.35 -5.44 -1.47 -1.26 -1.30

Competitive Comparison of Sonoma Pharmaceuticals's Earnings per Share (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Sonoma Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sonoma Pharmaceuticals's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sonoma Pharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where Sonoma Pharmaceuticals's PE Ratio falls into.



Sonoma Pharmaceuticals Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Sonoma Pharmaceuticals's Earnings Per Share (Diluted) for the fiscal year that ended in Mar. 2024 is calculated as

Diluted Earnings Per Share (A: Mar. 2024 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-4.448-0)/0.455
=-9.78

Sonoma Pharmaceuticals's Earnings Per Share (Diluted) for the quarter that ended in Jun. 2024 is calculated as

Diluted Earnings Per Share (Q: Jun. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-1.062-0)/0.851
=-1.25

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-9.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Sonoma Pharmaceuticals  (STU:O8Z) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Sonoma Pharmaceuticals Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Sonoma Pharmaceuticals's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Sonoma Pharmaceuticals Business Description

Traded in Other Exchanges
Address
5445 Conestoga Court, Suite 150, Boulder, CO, USA, 80301
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, and other countries.

Sonoma Pharmaceuticals Headlines

No Headlines